
[Pharmacopeial Forum Table of Contents](#)

View the current Pharmacopeial Forum (PF) Table of Contents. For older PF tables of contents, [visit our archive](#).

Select from the below links to access PF content. A free resource, PF visitors must create a user name and password.

PF 44(1) Table of Contents Publish date: November 1, 2017

PROPOSED IRA

- [Proposed Interim Revision Announcements](#)

USP MONOGRAPHS

IN-PROCESS REVISION

- [In-Process Revision](#)

GENERAL NOTICES FOR USP–NF

- [General Notices to USP–NF \(USP42–NF37\)](#)

1. [TITLE AND REVISION](#)
2. [OFFICIAL STATUS AND LEGAL RECOGNITION](#)
3. [CONFORMANCE TO STANDARDS](#)
4. [MONOGRAPHS AND GENERAL CHAPTERS](#)
5. [MONOGRAPH COMPONENTS](#)
6. [TESTING PRACTICES AND PROCEDURES](#)
7. [TEST RESULTS](#)
8. [TERMS AND DEFINITIONS](#)
9. [PRESCRIBING AND DISPENSING](#)
10. [PRESERVATION, PACKAGING, STORAGE, AND LABELING](#)

GENERAL CHAPTERS

- [<7> LABELING \(USP42–NF37\)](#)
- [<561> ARTICLES OF BOTANICAL ORIGIN \(USP42–NF37\)](#)
- [<1057> BIOTECHNOLOGY-DERIVED ARTICLES—TOTAL PROTEIN ASSAY \(USP42–NF37\)](#)
- [<1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE \(USP42–NF37\)](#)
- [<1176> PRESCRIPTION BALANCES AND VOLUMETRIC APPARATUS USED IN COMPOUNDING \(USP42–NF37\)](#)

REAGENTS, INDICATORS, AND SOLUTIONS

Reagent Specifications

- [Aflatoxin B1 \[NEW\] \(USP42–NF37\)](#)
- [Aflatoxin B2 \[NEW\] \(USP42–NF37\)](#)
- [Aflatoxin G1 \[NEW\] \(USP42–NF37\)](#)
- [Aflatoxin G2 \[NEW\] \(USP42–NF37\)](#)
- [Clozapine N-Oxide \[NEW\] \(USP42–NF37\)](#)
- [Deuterated Ethanol \[NEW\] \(USP42–NF37\)](#)
- [Deuterium Chloride Solution \[NEW\] \(USP42–NF37\)](#)
- [Deuterium Oxide \(USP42–NF37\)](#)
- [Isobutyl Chloroformate \[NEW\] \(USP42–NF37\)](#)
- [Polyethylene Glycol 400 \[NEW\] \(USP42–NF37\)](#)
- [Polyethylene Glycol 4000 \[NEW\] \(USP42–NF37\)](#)
- [Pyridine, Anhydrous \[NEW\] \(USP42–NF37\)](#)
- [Trifluoroacetic Acid Ethyl Ester \[NEW\] \(USP42–NF37\)](#)

Test Solutions

- [Citric Acid TS \[NEW\] \(USP42–NF37\)](#)
- [Sodium Chloride TS \[NEW\] \(USP42–NF37\)](#)

Volumetric Solutions

- [0.2 N Alcoholic Potassium Hydroxide VS \[NEW\] \(USP42–NF37\)](#)
- [0.002 M Edetate Disodium VS \[NEW\] \(USP42–NF37\)](#)
- [0.01 M Edetate Disodium VS \[NEW\] \(USP42–NF37\)](#)

REFERENCE TABLES

Container Specifications

- [Container Specifications \[NEW\] \(USP42–NF37\)](#)

Description and Solubility

- [Description and Relative Solubility of USP and NF Articles \[NEW\] \(USP42–NF37\)](#)
- [Description and Solubility - G](#)

USP MONOGRAPHS

- [Albuterol Inhalation Aerosol \[NEW\] \(USP42–NF37\)](#)
- [Ampicillin and Sulbactam for Injection \(USP42–NF37\)](#)
- [Atomoxetine Capsules \(USP42–NF37\)](#)
- [Bendroflumethiazide \(USP42–NF37\)](#)
- [Benzonatate \(USP42–NF37\)](#)
- [Betamethasone \(USP42–NF37\)](#)
- [Bisacodyl \(USP42–NF37\)](#)
- [Bumetanide \(USP42–NF37\)](#)

-
- [Bumetanide Injection \(USP42–NF37\)](#)
 - [Carbidopa and Levodopa Orally Disintegrating Tablets \(USP42–NF37\)](#)
 - [Cefixime \(USP42–NF37\)](#)
 - [Cefixime Capsules \[NEW\] \(USP42–NF37\)](#)
 - [Cefixime for Oral Suspension \(USP42–NF37\)](#)
 - [Cefixime Tablets \(USP42–NF37\)](#)
 - [Chromium Cr 51 Edetate Injection \(USP42–NF37\)](#)
 - [Desvenlafaxine Extended-Release Tablets \[NEW\] \(USP42–NF37\)](#)
 - [Diclofenac Sodium Topical Solution \[NEW\] \(USP42–NF37\)](#)
 - [Ertapenem Sodium \[NEW\] \(USP42–NF37\)](#)
 - [Ethosuximide \(USP42–NF37\)](#)
 - [Ethosuximide Capsules \(USP42–NF37\)](#)
 - [Ethosuximide Oral Solution \(USP42–NF37\)](#)
 - [Famciclovir Tablets \[NEW\] \(USP42–NF37\)](#)
 - [Fentanyl \(USP42–NF37\)](#)
 - [Fentanyl Citrate Compounded Injection \[NEW\] \(USP42–NF37\)](#)
 - [Fentanyl Citrate and Bupivacaine Hydrochloride Compounded Injection \[NEW\] \(USP42–NF37\)](#)
 - [Fentanyl Citrate and Ropivacaine Hydrochloride Compounded Injection \[NEW\] \(USP42–NF37\)](#)
 - [Heparin Lock Flush Solution \(USP42–NF37\)](#)
 - [Heparin Sodium Injection \(USP42–NF37\)](#)
 - [Hydrochlorothiazide Capsules \(USP42–NF37\)](#)
 - [Hydromorphone Hydrochloride \(USP42–NF37\)](#)
 - [Hypromellose Capsule Shell \(USP42–NF37\)](#)
 - [Inamrinone Injection \(USP42–NF37\)](#)
 - [Indium In 111 Ibritumomab Tiuxetan Injection \(USP42–NF37\)](#)
 - [Indium In 111 Satumomab Pendetide Injection \(USP42–NF37\)](#)
 - [Insulin \(USP42–NF37\)](#)
 - [Iobenguane I 131 Injection \(USP42–NF37\)](#)
 - [Iodohippurate Sodium I 123 Injection \(USP42–NF37\)](#)
 - [Iodohippurate Sodium I 131 Injection \(USP42–NF37\)](#)
 - [Rose Bengal Sodium I 131 Injection \(USP42–NF37\)](#)
 - [Levalbuterol Inhalation Solution \(USP42–NF37\)](#)
 - [Levalbuterol Hydrochloride \(USP42–NF37\)](#)
 - [Lovastatin Tablets \(USP42–NF37\)](#)
 - [Magnesium Hydroxide \(USP42–NF37\)](#)
 - [Metaraminol Bitartrate \(USP42–NF37\)](#)
 - [Mitoxantrone Injection \(USP42–NF37\)](#)
 - [Mitoxantrone Hydrochloride \(USP42–NF37\)](#)
 - [Nicotine Polacrilex \(USP42–NF37\)](#)
 - [Orphenadrine Citrate Injection \(USP42–NF37\)](#)
 - [Orphenadrine Citrate Extended-Release Tablets \(USP42–NF37\)](#)
 - [Oxazepam \(USP42–NF37\)](#)
 - [Phenylephrine Hydrochloride Nasal Solution \(USP42–NF37\)](#)
 - [Phenylephrine Hydrochloride Ophthalmic Solution \(USP42–NF37\)](#)
 - [Chromic Phosphate P 32 Suspension \(USP42–NF37\)](#)
 - [Sodium Phosphate P 32 Solution \(USP42–NF37\)](#)
 - [Pramipexole Dihydrochloride Tablets \[NEW\] \(USP42–NF37\)](#)
 - [Primidone Tablets \(USP42–NF37\)](#)

-
- [Propranolol Hydrochloride Injection \(USP42–NF37\)](#)
 - [Pyridostigmine Bromide \(USP42–NF37\)](#)
 - [Risperidone Orally Disintegrating Tablets \(USP42–NF37\)](#)
 - [Salicylic Acid Gel \(USP42–NF37\)](#)
 - [Sertraline Hydrochloride Tablets \(USP42–NF37\)](#)
 - [Suprofen \(USP42–NF37\)](#)
 - [Suprofen Ophthalmic Solution \(USP42–NF37\)](#)
 - [Technetium Tc 99m Albumin Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Albumin Colloid Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Apcitide Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Arcitumomab Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Depreotide Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Etidronate Injection \(USP42–NF37\)](#)
 - [Technetium 99mTc Fanolesomab Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Gluceptate Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Lidofenin Injection \(USP42–NF37\)](#)
 - [Technetium Tc 99m Nofetumomab Merpentan Injection \(USP42–NF37\)](#)
 - [Terbutaline Sulfate \(USP42–NF37\)](#)
 - [Terbutaline Sulfate Injection \(USP42–NF37\)](#)
 - [Terbutaline Sulfate Tablets \(USP42–NF37\)](#)
 - [Triamcinolone Acetonide Nasal Spray \(USP42–NF37\)](#)
 - [Valproic Acid Oral Solution \(USP42–NF37\)](#)
 - [Xenon Xe 127 \(USP42–NF37\)](#)
 - [Xenon Xe 133 Injection \(USP42–NF37\)](#)

DIETARY SUPPLEMENT MONOGRAPHS

- [Ashwagandha Root \(USP42–NF37\)](#)
- [Powdered Ashwagandha Root \(USP42–NF37\)](#)
- [Powdered Ashwagandha Root Extract \(USP42–NF37\)](#)
- [Bitter Orange Fruit Flavonoids Dry Extract \[NEW\] \(USP42–NF37\)](#)
- [Krill Oil Capsules \(USP42–NF37\)](#)
- [Krill Oil Delayed-Release Capsules \(USP42–NF37\)](#)
- [Lycopene \(USP42–NF37\)](#)
- [Lycopene Preparation \(USP42–NF37\)](#)
- [Tomato Extract Containing Lycopene \(USP42–NF37\)](#)
- [Tienchi Ginseng Root and Rhizome \(USP42–NF37\)](#)
- [Tienchi Ginseng Root and Rhizome Powder \(USP42–NF37\)](#)
- [Tienchi Ginseng Root and Rhizome Powder Capsules \(USP42–NF37\)](#)
- [Tienchi Ginseng Root and Rhizome Powder Tablets \(USP42–NF37\)](#)
- [Tienchi Ginseng Root and Rhizome Dry Extract \(USP42–NF37\)](#)
- [Tienchi Ginseng Root and Rhizome Dry Extract Capsules \(USP42–NF37\)](#)
- [Tienchi Ginseng Root and Rhizome Dry Extract Tablets \(USP42–NF37\)](#)

NF MONOGRAPHS

- [Butylated Hydroxyanisole \(USP42–NF37\)](#)

STAGE 4 HARMONIZATION

-
- [Stage 4 Harmonization](#)

GENERAL CHAPTERS

- [<1055> BIOTECHNOLOGY-DERIVED ARTICLES—PEPTIDE MAPPING](#)

STIMULI TO THE REVISION PROCESS

- [STIMULI TO THE REVISION PROCESS](#)